Glycoside hydrolases and their use in preventing and/or treating a pathogenic infection in an animal
Disclosed are methods and compositions using glycoside hydrolases, such as an alpha-L-fucosidases, to prevent and/or treat a pathogenic infection and/or diarrhea in an animal wherein the pathogenic infection is caused by a pathogen capable of binding to an animal intestinal cell wherein said binding of the pathogen is dependent on the presence of a pathogen binding site having at least one glycan structure substituted with at least one alpha-1,2-L-fucose moiety comprising administering to the animal an effective amount of a glycoside hydrolase capable of removing the at least one alpha-1,2-L-fucose moiety from the pathogen binding site.
1. A method of treating an animal with an intestinal pathogenic infection and/or diarrhea wherein the pathogenic infection and/or diarrhea is caused by a pathogen capable of binding to an animal intestinal cell wherein said binding of the pathogen is dependent on the presence of a pathogen binding site having at least one glycan structure substituted with at least one alpha-1,2-L-fucose moiety comprising administering to the animal an effective amount of a purified glycoside hydrolase family 95 (GH95) alpha-L-fucosidase capable of removing the at least one alpha-1,2-L-fucose moiety from the pathogen binding site.
2. The method of claim 1 wherein the GH95 alpha-L-fucosidase is capable of removing a terminal alpha-1,2-linked fucose group from a glycan-containing structure.
3. The method of claim 1 wherein the pathogen is Escherichia coli expressing F18 fimbriae.
4. The method of claim 1 wherein the method further comprises administering to the animal an effective amount of a GH95 alpha-L-fucosidase in combination with at least one direct fed microbial.
5. The method of claim 4 wherein the method further comprises administering to the animal an effective amount a GH95 alpha-L-fucosidase in combination with at least one direct fed microbial and at least one protease.
6. The method of claim 5 wherein the GH95 alpha-L-fucosidase and/or the direct fed microbial and/or the protease are administered in an animal feed or a premix.
7. The method of claim 4 wherein the GH95 alpha-L-fucosidase is encapsulated.
8. The method of claim 4 wherein the GH95 alpha-L-fucosidase and/or the direct fed microbial are administered in an animal feed or a premix.
9. The method of claim 4 wherein the GH95 alpha-L-fucosidase is in the form of a granule.
10. The method of claim 1 wherein the GH95 alpha-L-fucosidase is encapsulated.
11. The method of claim 1 wherein the GH95 alpha-L-fucosidase is in the form of a granule.
12. The method of claim 1 , wherein the GH95 alpha-L-fucosidase is derived from Bifidobacterium bifidum, Bifidobacterium longum, Bacteroides fragilis , or Bacteroides helcogenes.
13. The method of claim 1 , further comprising administering an enzyme capable of (a) converting a blood group A antigen to a blood group H antigen or (b) converting a blood group B antigen to blood group H antigen.
14. The method of claim 13 , wherein the enzyme capable of converting a blood group A antigen to a blood group H antigen is an alpha-N-acetylgalactosidase.
15. The method of claim 13 , wherein the enzyme capable of converting a blood group B antigen to blood group H antigen is an alpha-galactosidase.